Gene:
CYP3A4
cytochrome P450, family 3, subfamily A, polypeptide 4

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.


Annotated Labels

  1. FDA Label for ticagrelor and CYP3A4,CYP3A5
  2. EMA Label for aripiprazole and CYP2D6,CYP3A4
  3. EMA Label for cabazitaxel and CYP3A4
  4. EMA Label for darunavir and CYP3A4
  5. EMA Label for dronedarone and CYP2D6,CYP3A4
  6. EMA Label for fosamprenavir and CYP3A4
  7. EMA Label for gefitinib and CYP2D6,CYP3A4,EGFR
  8. EMA Label for indinavir and CYP3A4
  9. EMA Label for ivabradine and CYP3A4
  10. EMA Label for nelfinavir and CYP3A4
  11. EMA Label for posaconazole and CYP3A4
  12. EMA Label for ritonavir and CYP2D6,CYP3A4
  13. EMA Label for ruxolitinib and CYP3A4
  14. EMA Label for sirolimus and CYP3A4
  15. EMA Label for sunitinib and CYP3A4
  16. EMA Label for telithromycin and CYP3A4
  17. EMA Label for tipranavir and CYP3A4
  18. EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4
  19. EMA Label for zonisamide and CYP3A4

last updated 10/25/2013

1. FDA Label for ticagrelor and CYP3A4,CYP3A5

Informative PGx

Summary

Ticagrelor is a platelet inhibitor used to reduce the risk of thrombotic cardiovascular events for patients with acute coronary syndrome. It is metabolized by CYP3A4/5; the label advises against using the drug in conjunction with CYP3A inhibitors and inducers.

There's more of this label. Read more.


last updated 10/25/2013

2. EMA Label for aripiprazole and CYP2D6,CYP3A4

Actionable PGx

Summary

The EMA European Public Assessment Report (EPAR) recommends dose adjustments when aripiprazole is taken with CYP3A4 inhibitors in CYP2D6 poor metabolizers, or concomitant use of CYP3A4 or CYP2D6 inhibitors, or CYP3A4 inducers.

There's more of this label. Read more.


last updated 08/21/2014

3. EMA Label for cabazitaxel and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for cabazitaxel (Jevtana) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A, and coadministration of strong CYP3A inhibitors or inducers should be avoided.

There's more of this label. Read more.


last updated 09/17/2014

4. EMA Label for darunavir and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for darunavir (PREZISTA) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of darunavir by CYP3A and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.

There's more of this label. Read more.


last updated 09/16/2014

5. EMA Label for dronedarone and CYP2D6,CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for dronedarone (MULTAQ) states that it is a mild inhibitor of CYP2D6, and that the effect on metoprolol and propranol exposure is much below the difference seen between poor and extensive CYP2D6 metabolisers. It also contains information regarding metabolism of by dronedarone CYP3A4, and that concomitant drugs that are potent CYP3A4 inhibitors are contraindicated and potent CYP3A4 inducers are not recommended.

There's more of this label. Read more.


last updated 09/16/2014

6. EMA Label for fosamprenavir and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for fosamprenavir (Telzir) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. Concomitant use of drugs with a narrow therapeutic window that are substrates of CYP3A4 or CYP2D6 is contraindicated.

There's more of this label. Read more.


last updated 10/25/2013

7. EMA Label for gefitinib and CYP2D6,CYP3A4,EGFR

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) contains biomarker information regarding the indication of gefitinib (Iressa) in patients with tumors that have activating EGFR mutations, due to its mechanism of action.

There's more of this label. Read more.


last updated 09/16/2014

8. EMA Label for indinavir and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for indinavir (Crixivan) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and contraindicates concomitant use of drugs that are CYP3A4 substrates.

There's more of this label. Read more.


last updated 09/16/2014

9. EMA Label for ivabradine and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for ivabradine (Corlentor) does not contain pharmacogenetic information. It contains information regarding metabolism of ivabradine by CYP3A4, and that concomitant use of potent CYP3A4 inhibitors is contraindicated.

There's more of this label. Read more.


last updated 10/27/2013

10. EMA Label for nelfinavir and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for nelfinavir (Viracept) contains information regarding the metabolism of the drug by CYP3A4, CYP2C19 and CYP2D6, and that concomitant use of CYP3A4 substrates or inducers is contraindicated. No genetic information is included.

There's more of this label. Read more.


last updated 09/16/2014

11. EMA Label for posaconazole and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for posaconazole (Noxafil) does not contain pharmacogenetic information. It contains information regarding metabolism drug-drug interactions with CYP3A4 substrates.

There's more of this label. Read more.


last updated 09/15/2014

12. EMA Label for ritonavir and CYP2D6,CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for ritonavir (Norvir) does not contain pharmacogenetic information. It contains information regarding use of ritonavir as a pharmacokinetic enhancer for certain drugs to prolong their therapeutic effects. It is a potent inhibitor of CYP3A and CYP2D6-mediated biotransformation, and the EPAR provides a list of drugs contraindicated for concomitant use with ritonavir.

There's more of this label. Read more.


last updated 09/12/2014

13. EMA Label for ruxolitinib and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for ruxolitinib (Jakavi) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and CYP2C9, and suggests dosing adjustments and more frequent monitoring of hematology parameters if co-administered with strong CYP3A4 inhibitors or inducers, or dual inhibitors of CYP3A4 and CYP2C9.

There's more of this label. Read more.


last updated 09/15/2014

14. EMA Label for sirolimus and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for sirolimus (Rapamune) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends therapeutic monitoring and dose adjustments when coadministrated with strong CYP3A inhibitors or inducers.

There's more of this label. Read more.


last updated 09/16/2014

15. EMA Label for sunitinib and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for sunitinib (SUTENT) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and that potent CYP3A4 inhibitors or inducers should be avoided as they may affect sunitinib plasma levels.

There's more of this label. Read more.


last updated 09/16/2014

16. EMA Label for telithromycin and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for telithromycin (Ketek) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and contains information regarding use of concomitant drugs that are CYP3A4 substrates, inhibitors or inducers.

There's more of this label. Read more.


last updated 09/17/2014

17. EMA Label for tipranavir and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for tipranavir (Aptivus) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of tipranavir by CYP3A4, and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.

There's more of this label. Read more.


last updated 08/06/2014

18. EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) does not contain pharmacogenetic information. It contains warning information regarding the co-administration of drugs that are substrates, inhibitors or activators of CYP3A4, CYP2C9 or CYP2C19 due to drug-drug interactions.

There's more of this label. Read more.


last updated 09/16/2014

19. EMA Label for zonisamide and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for zonisamide (Zonegran) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends dose adjustments if CYP3A4 inducers are taken concomitantly.

There's more of this label. Read more.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for CYP3A4

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA *1 N/A N/A N/A
No VIP available No VIP available VA *1A N/A N/A N/A
No VIP available No VIP available VA *1B N/A N/A N/A
No VIP available CA VA *1G N/A N/A N/A
No VIP available No VIP available VA *2 N/A N/A N/A
No VIP available No VIP available VA *3 N/A N/A N/A
No VIP available CA VA *4 N/A N/A N/A
No VIP available No VIP available VA *7 N/A N/A N/A
No VIP available CA VA *8 N/A N/A N/A
No VIP available No VIP available VA *9 N/A N/A N/A
No VIP available No VIP available VA *11 N/A N/A N/A
No VIP available No VIP available VA *12 N/A N/A N/A
No VIP available No VIP available VA *18 N/A N/A N/A
No VIP available No VIP available VA *18B N/A N/A N/A
No VIP available CA VA *20 N/A N/A N/A
No VIP available CA VA *22 N/A N/A N/A
rs12333983 NC_000007.13:g.99354114T>A, NC_000007.14:g.99756491T>A, NG_008421.1:g.32695A>T, NM_001202855.2:c.*1642A>T, NM_017460.5:c.*1642A>T, XM_011515841.1:c.*1642A>T, XM_011515842.1:c.*1642A>T, rs61591143
T > A
SNP
rs12721627 NC_000007.13:g.99366093G>C, NC_000007.14:g.99768470G>C, NG_008421.1:g.20716C>G, NM_001202855.2:c.554C>G, NM_017460.5:c.554C>G, NP_001189784.1:p.Thr185Ser, NP_059488.2:p.Thr185Ser, XM_011515841.1:c.554C>G, XM_011515842.1:c.554C>G, XP_011514143.1:p.Thr185Ser, XP_011514144.1:p.Thr185Ser, rs28371754, rs56915287
G > C
SNP
T185S
rs12721634 NC_000007.13:g.99381661A>G, NC_000007.14:g.99784038A>G, NG_008421.1:g.5148T>C, NM_001202855.2:c.44T>C, NM_017460.5:c.44T>C, NP_001189784.1:p.Leu15Pro, NP_059488.2:p.Leu15Pro, XM_011515841.1:c.44T>C, XM_011515842.1:c.44T>C, XP_011514143.1:p.Leu15Pro, XP_011514144.1:p.Leu15Pro, rs386525810
A > G
SNP
L15P
rs1851426 NC_000007.13:g.99382936A>G, NC_000007.14:g.99785313A>G, NG_008421.1:g.3873T>C, NM_001202855.2:c.-1232T>C, NM_017460.5:c.-1232T>C, XM_011515841.1:c.-1232T>C, XM_011515842.1:c.-1232T>C, rs56476282, rs57950778
A > G
SNP
rs2242480 NC_000007.13:g.99361466C>T, NC_000007.14:g.99763843C>T, NG_008421.1:g.25343G>A, NM_001202855.2:c.1023+12G>A, NM_017460.5:c.1026+12G>A, XM_011515841.1:c.1026+12G>A, XM_011515842.1:c.1023+12G>A, rs10364667, rs12721630, rs17161804, rs28969389, rs59491337, rs72494459, rs9655766
C > T
SNP
rs2246709 NC_000007.13:g.99365719A>G, NC_000007.14:g.99768096A>G, NG_008421.1:g.21090T>C, NM_001202855.2:c.670+258T>C, NM_017460.5:c.670+258T>C, XM_011515841.1:c.670+258T>C, XM_011515842.1:c.670+258T>C, rs56901335
A > G
SNP
rs2687116 NC_000007.13:g.99365943C>A, NC_000007.14:g.99768320C>A, NG_008421.1:g.20866G>T, NM_001202855.2:c.670+34G>T, NM_017460.5:c.670+34G>T, XM_011515841.1:c.670+34G>T, XM_011515842.1:c.670+34G>T, rs17161901, rs59381366
C > A
SNP
rs2740574 NC_000007.13:g.99382096C>T, NC_000007.14:g.99784473C>T, NG_008421.1:g.4713G>A, NM_001202855.2:c.-392G>A, NM_017460.5:c.-392G>A, XM_011515841.1:c.-392G>A, XM_011515842.1:c.-392G>A, rs3176920, rs36231114, rs59393892
C > T
SNP
rs28371759 NC_000007.13:g.99361626A>G, NC_000007.14:g.99764003A>G, NG_008421.1:g.25183T>C, NM_001202855.2:c.875T>C, NM_017460.5:c.878T>C, NP_001189784.1:p.Leu292Pro, NP_059488.2:p.Leu293Pro, XM_011515841.1:c.878T>C, XM_011515842.1:c.875T>C, XP_011514143.1:p.Leu293Pro, XP_011514144.1:p.Leu292Pro, rs386574775, rs60608883
A > G
SNP
L292P
rs35599367 NC_000007.13:g.99366316G>A, NC_000007.14:g.99768693G>A, NG_008421.1:g.20493C>T, NM_001202855.2:c.522-191C>T, NM_017460.5:c.522-191C>T, XM_011515841.1:c.522-191C>T, XM_011515842.1:c.522-191C>T, rs45581939, rs62471940
G > A
SNP
rs3735451 NC_000007.13:g.99355975T>C, NC_000007.14:g.99758352T>C, NG_008421.1:g.30834A>G, NM_001202855.2:c.1414-124A>G, NM_017460.5:c.1417-124A>G, XM_011515841.1:c.1510-124A>G, XM_011515842.1:c.1507-124A>G, rs386585004, rs57555923
T > C
SNP
rs4646437 NC_000007.13:g.99365083G>A, NC_000007.14:g.99767460G>A, NG_008421.1:g.21726C>T, NM_001202855.2:c.671-205C>T, NM_017460.5:c.671-202C>T, XM_011515841.1:c.671-202C>T, XM_011515842.1:c.671-205C>T, rs386594232, rs57997883
G > A
SNP
rs4646440 NC_000007.13:g.99360870G>A, NC_000007.14:g.99763247G>A, NG_008421.1:g.25939C>T, NM_001202855.2:c.1023+608C>T, NM_017460.5:c.1026+608C>T, XM_011515841.1:c.1026+608C>T, XM_011515842.1:c.1023+608C>T, rs386594233, rs56791612
G > A
SNP
rs4986907 NC_000007.13:g.99367427C>T, NC_000007.14:g.99769804C>T, NG_008421.1:g.19382G>A, NM_001202855.2:c.485G>A, NM_017460.5:c.485G>A, NP_001189784.1:p.Arg162Gln, NP_059488.2:p.Arg162Gln, XM_011515841.1:c.485G>A, XM_011515842.1:c.485G>A, XP_011514143.1:p.Arg162Gln, XP_011514144.1:p.Arg162Gln, rs58254554
C > T
SNP
R162Q
rs4986908 NC_000007.13:g.99367392C>T, NC_000007.14:g.99769769C>T, NG_008421.1:g.19417G>A, NM_001202855.2:c.520G>A, NM_017460.5:c.520G>A, NP_001189784.1:p.Asp174Asn, NP_059488.2:p.Asp174Asn, XM_011515841.1:c.520G>A, XM_011515842.1:c.520G>A, XP_011514143.1:p.Asp174Asn, XP_011514144.1:p.Asp174Asn, rs386597003, rs58133974
C > T
SNP
D174N
rs4986909 NC_000007.13:g.99359670G>A, NC_000007.14:g.99762047G>A, NG_008421.1:g.27139C>T, NM_001202855.2:c.1244C>T, NM_017460.5:c.1247C>T, NP_001189784.1:p.Pro415Leu, NP_059488.2:p.Pro416Leu, XM_011515841.1:c.1247C>T, XM_011515842.1:c.1244C>T, XP_011514143.1:p.Pro416Leu, XP_011514144.1:p.Pro415Leu, rs386597004
G > A
SNP
P415L
rs4986910 NC_000007.13:g.99358524A>G, NC_000007.14:g.99760901A>G, NG_008421.1:g.28285T>C, NM_001202855.2:c.1331T>C, NM_017460.5:c.1334T>C, NP_001189784.1:p.Met444Thr, NP_059488.2:p.Met445Thr, XM_011515841.1:c.1427T>C, XM_011515842.1:c.1424T>C, XP_011514143.1:p.Met476Thr, XP_011514144.1:p.Met475Thr, rs386597005, rs60835115
A > G
SNP
M444T
rs4986913 NC_000007.13:g.99358459G>A, NC_000007.14:g.99760836G>A, NG_008421.1:g.28350C>T, NM_001202855.2:c.1396C>T, NM_017460.5:c.1399C>T, NP_001189784.1:p.Pro466Ser, NP_059488.2:p.Pro467Ser, XM_011515841.1:c.1492C>T, XM_011515842.1:c.1489C>T, XP_011514143.1:p.Pro498Ser, XP_011514144.1:p.Pro497Ser, rs386597007
G > A
SNP
P466S
rs4986914 NC_000007.13:g.99382233A>G, NC_000007.14:g.99784610A>G, NG_008421.1:g.4576T>C, NM_001202855.2:c.-529T>C, NM_017460.5:c.-529T>C, XM_011515841.1:c.-529T>C, XM_011515842.1:c.-529T>C
A > G
SNP
rs4987161 NC_000007.13:g.99366081A>G, NC_000007.14:g.99768458A>G, NG_008421.1:g.20728T>C, NM_001202855.2:c.566T>C, NM_017460.5:c.566T>C, NP_001189784.1:p.Phe189Ser, NP_059488.2:p.Phe189Ser, XM_011515841.1:c.566T>C, XM_011515842.1:c.566T>C, XP_011514143.1:p.Phe189Ser, XP_011514144.1:p.Phe189Ser
A > G
SNP
F189S
rs56324128 NC_000007.13:g.99375702C>T, NC_000007.14:g.99778079C>T, NG_008421.1:g.11107G>A, NM_001202855.2:c.167G>A, NM_017460.5:c.167G>A, NP_001189784.1:p.Gly56Asp, NP_059488.2:p.Gly56Asp, XM_011515841.1:c.167G>A, XM_011515842.1:c.167G>A, XP_011514143.1:p.Gly56Asp, XP_011514144.1:p.Gly56Asp, rs386626576, rs59765626
C > T
SNP
G56D
rs6956344 NC_000007.13:g.99359151C>T, NC_000007.14:g.99761528C>T, NG_008421.1:g.27658G>A, NM_001202855.2:c.1250+513G>A, NM_017460.5:c.1253+513G>A, XM_011515841.1:c.1346+248G>A, XM_011515842.1:c.1343+248G>A
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  CYP3A3
Alternate Symbols:  None
PharmGKB Accession Id: PA130

Details

Cytogenetic Location: chr7 : q22.1 - q22.1
GP mRNA Boundary: chr7 : 99354583 - 99381811
GP Gene Boundary: chr7 : 99351583 - 99391811
Strand: minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Note: The CYP3A4 gene is found on the minus chromosomal strand. Please note that for standardization, the PharmGKB presents all allele base pairs on the positive chromosomal strand; therefore the alleles within our variant annotations will differ (in a complementary manner) from those in this VIP summary that are given on the minus strand as reported in the literature.

CYP3A4 (cytochrome P450 3A4) encodes a member of the cytochrome P450 superfamily of enzymes. CYP3A4 and CYP3A5 are believed to be the predominant cytochrome P450s expressed in adult human liver, with CYP3A4 thought to dominate in Whites and CYP3A5 in Blacks/African Americans. The two have overlapping substrate specificities. CYP3A4 is responsible for the metabolism of approximately 50-60% of clinical drugs used today, including acetaminophen, codeine, cyclosporine A, diazepam, and erythromycin. It is important for the metabolism of steroid hormones [Articles:9667077, 9054608, 9187528, 3259858].

The complete cDNA sequence was reported by Molowa et al. in 1986 [Article:3460094], and Inoue et al. later mapped the gene to 7q22.1 by fluorescence in situ hybridization [Article:1391968]. The gene is about 27 kb in length and contains 13 exons and 12 introns [Article:8269949].

Linkage results from a Japanese population [Article:14695543] demonstrate that CYP3A4 and CYP3A5 haplotypes are closely linked and that the two genes are in the same gene block, so some effects originally thought to be due to a CYP3A4 allele are probably actually due to a CYP3A5 allele in linkage disequilibrium.

Though extensively studied, most of the CYP3A4 haplotypes have not been indisputably shown to affect expression or activity in terms of pharmacodynamics or pharmacokinetics. One recently discovered rare haplotype, CYP3A4*20, contains a premature stop codon which does result in a truncated protein and complete loss of function [Article:16580902]; this publication also contains excellent overview information for CYP3A4. This haplotype has been identified in only one family (of Brazilian origin) to date.

The g.82,266 (on AF280107 ) polymorphism (part of haplotypes *18B and *19 ) may contribute to variability in response to clopidogrel (which requires metabolism by CYP3A4 to be active). This study was done in a Spanish (White) population of coronary artery disease patients also being treated with aspirin [Article:16645157].
The *16B haplotype has been reported to result in altered paclitaxel metabolite levels in Japanese (Asian) cancer patients [Article:16890579]. One study showed that cancer patients carrying CYP3A4*1B may have a higher rate of docetaxel clearance and so a lower exposure to docetaxel [Article:16765145], though this actually may be due to the linked CYP3A5*1. However, Lewis et al. [Article:17545536] found no significant relationship between CYP3A4*1B and docetaxol clearance in African American (Black or African American) and Caucasian(White) cancer patients.

Chu et al. recently found that white female breast cancer patients who are CYP3A4 *1B carriers may have an increased risk of developing endometrial cancer after tamoxifen treatment when compared with non -*1B carriers [Article:17434921].

In vitro, CYP3A*1B has been reported to lead to increased transcription [Article:14673875], though there have been conflicting results as well [Article:14515058].

Also see Lamba et al. [Article:12406645], Lee and Goldstein[Article:16004554]http://www.imm.ki.se/cypalleles/cyp3a4.htm .

Citation
M. Whirl-Carrillo, E.M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, R.B. Altman and T.E. Klein. "Pharmacogenomics Knowledge for Personalized Medicine" Clinical Pharmacology & Therapeutics (2012) 92(4): 414-417. Full text
History

Submitted by Alan Shuldiner (PAPI), Michelle Whirl Carillo(PharmGKB), Joan M. Hebert(PharmGKB)

Key Publications
  1. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis. 2007. Chu William, Fyles Anthony, Sellers Edward M, McCready David R, Murphy Joan, Pal Tuya, Narod Steven A. PubMed
  2. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007. Lewis Lionel D, Miller Antonius A, Rosner Gary L, Dowell Jonathan E, Valdivieso Manuel, Relling Mary V, Egorin Merrill J, Bies Robert R, Hollis Donna R, Levine Ellis G, Otterson Gregory A, Millard Frederick, Ratain Mark J, Cancer and Leukemia Group B. PubMed
  3. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clinical pharmacology and therapeutics. 2006. Nakajima Yukiko, Yoshitani Takashi, Fukushima-Uesaka Hiromi, Saito Yoshiro, Kaniwa Nahoko, Kurose Kouichi, Ozawa Shogo, Aoyagi Nobuo, Kamatani Naoyuki, Yamamoto Noboru, Kunitoh Hideo, Ohe Yuichiro, Tamura Tomohide, Yoshida Teruhiko, Minami Hironobu, Saijo Nagahiro, Katori Noriko, Sawada Jun-ichi. PubMed
  4. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clinical pharmacology and therapeutics. 2006. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Tréluyer J M. PubMed
  5. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arteriosclerosis, thrombosis, and vascular biology. 2006. Angiolillo Dominick J, Fernandez-Ortiz Antonio, Bernardo Esther, Ramírez Celia, Cavallari Ugo, Trabetti Elisabetta, Sabaté Manel, Hernández Rosana, Moreno Raul, Escaned Javier, Alfonso Fernando, Bañuelos Camino, Costa Marco A, Bass Theodore A, Pignatti Pier Franco, Macaya Carlos. PubMed
  6. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clinical pharmacology and therapeutics. 2006. Westlind-Johnsson Anna, Hermann Robert, Huennemeyer Andreas, Hauns Bernhard, Lahu Gezim, Nassr Nassr, Zech Karl, Ingelman-Sundberg Magnus, von Richter Oliver. PubMed
  7. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics. 2005. Lee Su-Jun, Goldstein Joyce A. PubMed
  8. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Human mutation. 2004. Fukushima-Uesaka Hiromi, Saito Yoshiro, Watanabe Hidemi, Shiseki Kisho, Saeki Mayumi, Nakamura Takahiro, Kurose Kouichi, Sai Kimie, Komamura Kazuo, Ueno Kazuyuki, Kamakura Shiro, Kitakaze Masafumi, Hanai Sotaro, Nakajima Toshiharu, Matsumoto Kenji, Saito Hirohisa, Goto Yu-ichi, Kimura Hideo, Katoh Masaaki, Sugai Kenji, Minami Narihiro, Shirao Kuniaki, Tamura Tomohide, Yamamoto Noboru, Minami Hironobu, Ohtsu Atsushi, Yoshida Teruhiko, Saijo Nagahiro, Kitamura Yutaka, Kamatani Naoyuki, Ozawa Shogo, Sawada Jun-ichi. PubMed
  9. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics. 2003. Floyd Michael D, Gervasini Guillermo, Masica Andrew L, Mayo Gail, George Alfred L, Bhat Kolari, Kim Richard B, Wilkinson Grant R. PubMed
  10. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environmental and molecular mutagenesis. 2003. Amirimani B, Ning B, Deitz A C, Weber B L, Kadlubar F F, Rebbeck T R. PubMed
  11. Genetic contribution to variable human CYP3A-mediated metabolism. Advanced drug delivery reviews. 2002. Lamba Jatinder K, Lin Yvonne S, Schuetz Erin G, Thummel Kenneth E. PubMed
  12. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clinical pharmacology and therapeutics. 2000. Sata F, Sapone A, Elizondo G, Stocker P, Miller V P, Zheng W, Raunio H, Crespi C L, Gonzalez F J. PubMed
  13. Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica; the fate of foreign compounds in biological systems. 1998. Niwa T, Yabusaki Y, Honma K, Matsuo N, Tatsuta K, Ishibashi F, Katagiri M. PubMed
  14. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis. 1997. Shou M, Korzekwa K R, Brooks E N, Krausz K W, Gonzalez F J, Gelboin H V. PubMed
  15. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug metabolism reviews. 1997. Rendic S, Di Carlo F J. PubMed
  16. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. European journal of biochemistry / FEBS. 1993. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T. PubMed
  17. Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. The Japanese journal of human genetics. 1992. Inoue K, Inazawa J, Nakagawa H, Shimada T, Yamazaki H, Guengerich F P, Abe T. PubMed
  18. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Archives of biochemistry and biophysics. 1988. Waxman D J, Attisano C, Guengerich F P, Lapenson D P. PubMed
  19. Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. Proceedings of the National Academy of Sciences of the United States of America. 1986. Molowa D T, Schuetz E G, Wrighton S A, Watkins P B, Kremers P, Mendez-Picon G, Parker G A, Guzelian P S. PubMed
Variant Summaries rs12721627, rs12721634, rs2740574, rs4986907, rs4986908, rs4986909, rs4986910, rs4986913, rs4987161
Haplotype Summaries CYP3A4*1A, CYP3A4*1B (CYP3A4-V) , CYP3A4*1C, CYP3A4*1D, CYP3A4*1E, CYP3A4*1F, CYP3A4*1G, CYP3A4*1H, CYP3A4*1J , CYP3A4*1K, CYP3A4*1L, CYP3A4*1M, CYP3A4*1N, CYP3A4*1P, CYP3A4*1Q, CYP3A4*1R, CYP3A4*1S, CYP3A4*1T, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15A, CYP3A4*15B, CYP3A4*16A, CYP3A4*16B, CYP3A4*17, CYP3A4*18A, CYP3A4*18B, CYP3A4*19, CYP3A4*20
Drugs
Drug Substrate (72)
alfentanil, alprazolam, amlodipine, aprepitant, aripiprazole, astemizole, atorvastatin, buspirone, caffeine, cerivastatin, chlorpheniramine, cilostazol, cisapride, clarithromycin, cocaine, codeine, cyclosporine, dapsone, dextromethorphan, diazepam, diltiazem, docetaxel, domperidone, eplerenone, erythromycin, estradiol, felodipine, fentanyl, finasteride, haloperidol, hydrocortisone, imatinib, indinavir, irinotecan, lercanidipine, levomethadyl acetate, lidocaine, lovastatin, methadone, midazolam, nateglinide, nelfinavir, nifedipine, nisoldipine, nitrendipine, ondansetron, paclitaxel, pimozide, progesterone, propranolol, quetiapine, quinidine, quinine, risperidone, ritonavir, salmeterol, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tamoxifen, telithromycin, terfenadine, testosterone, trazodone, triazolam, verapamil, vincristine, zaleplon, ziprasidone, zolpidem
Diseases
Pathways

Haplotype Overview

Haplotypes are derived from the Human Cytochrome P450 (CYP) Allele Nomenclature Database (version 3/5/2012 plus changes up to 11/25/2013; PharmGKB update 3/12/2014). The Human Cytochrome P450 (CYP) Allele Nomenclature Database states that nucleotide changes listed below are based on NCBI Reference Sequence AF280107.1. Note that the nucleotide positions from the Human Cytochrome P450 (CYP) Allele Nomenclature Database do not directly match the given NCBI reference sequence. For questions about nucleotide positions, please contact the Human Cytochrome P450 (CYP) Allele Nomenclature Database directly, as they are the authoritative source on cytochrome P450 nomenclature.

PharmGKB has added some alleles below (e.g. the row for *1), inserted for star alleles with subgroups (e.g. A, B etc). These rows reflect only the defining SNP for the star allele to accommodate how the star allele is referred to in the literature.

Source: PharmGKB

Haplotypes for CYP3A4

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Acetaminophen Pathway (therapeutic doses), Pharmacokinetics
    Stylized diagram showing acetaminophen metabolism and transport in the liver.
  1. Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics
    Nateglinide metabolism and transport in liver cell
  1. Anti-diabetic Drug Repaglinide Pathway, Pharmacokinetics
    Repaglinide metabolism and transport in a liver cell.
  1. Artemisinin and Derivatives Pathway, Pharmacokinetics
    Genes involved in the pharmacokinetics of the antimalarial drugs artemisinin, arsenate, artemether, and arteether.
  1. Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Benzodiazepine Pathway, Pharmacokinetics
    Diagrammatic representation of the metabolism of different benzodiazepine drugs by candidate genes.
  1. Caffeine Pathway, Pharmacokinetics
    Stylized liver cell showing candidate genes involved in the metabolism of caffeine.
  1. Carbamazepine Pathway, Pharmacokinetics
    Stylized liver cell depicting candidate genes involved in the pharmacokinetics of carbamazepine.
  1. Celecoxib Pathway, Pharmacokinetics
    Schematic representation of celecoxib metabolism in human liver cell.
  1. Citalopram Pathway, Pharmacokinetics
    Pharmacokinetics of the selective serotonin reuptake inhibitor citalopram.
  1. Clomipramine Pathway, Pharmacokinetics
    Schematic representation of clomipramine metabolism in human liver.
  1. Clopidogrel Pathway, Pharmacokinetics
    Representation of genes involved in metabolism of clopidogrel.
  1. Codeine and Morphine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in metabolism of codeine and morphine.
  1. Cyclophosphamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of cyclophosphamide.
  1. Doxepin Pathway, Pharmacokinetics
    Stylized liver cell showing candidate genes involved in the metabolism of the tricyclic doxepin.
  1. Efavirenz Pathway, Pharmacokinetics/Pharmacodynamics
    Schematic representation of efavirenz metabolism and mechanism of action against HIV.
  1. Erlotinib Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the transportation and metabolism of Erlotinib.
  1. Etoposide Pathway, Pharmacokinetics/Pharmacodynamics
    Etoposide cellular disposition and effects.
  1. Fluoxetine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of fluoxetine.
  1. Fluvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Gefitinib Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the transportation and metabolism of gefitinib.
  1. Glucocorticoid Pathway - Transcription Regulation, Pharmacodynamics
    Model displaying genes which may be involved in the nuclear complex formed that regulates transcription in response to glucocorticoids.
  1. Ibuprofen Pathway, Pharmacokinetics
    Stylized diagram of metabolism and transport of ibuprofen in the liver and kidney.
  1. Ifosfamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of ifosfamide.
  1. Imipramine/Desipramine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of the tricyclic antidepressants imipramine and desipramine.
  1. Irinotecan Pathway, Pharmacokinetics
    Model human liver cell showing blood, bile and intestinal compartments, indicating tissue specific involvement of genes in the irinotecan pathway.
  1. Ivacaftor pathway, pharmacokinetics/pharmacodynamics
    Stylized liver cell showing genes involved in the metabolism of ivacaftor, and stylized epithelial cell showing the potentiation of CFTR gating with ivacaftor treatment alone and with ivacftor plus lumacaftor treatment.
  1. Losartan Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of losartan.
  1. Macrolide Pharmacokinetics/Pharmacodynamics
    Stylized depiction of the genes involved in the transport, metabolism and mechanism of action of the macrolide antibiotics erythromycin, clarithromycin, and azithromycin.
  1. Metformin Pathway, Pharmacodynamics
    Simplified diagram of mechanism of action of metformin.
  1. Mycophenolic acid Pathway, Pharmacokinetics/Pharmacodynamics
    Schematic representation of mycophenolic acid metabolism.
  1. Nevirapine Pathway, Pharmacokinetics
    Representation of candidate genes involved in biotransformation of nevirapine and its mechanism of action in an infected liver cell.
  1. Paroxetine Pathway, Pharmacokinetics
    Genes involved in the metabolism of paroxetine and in the mechanism of action.
  1. Phenytoin Pathway, Pharmacokinetics
    Genes involved in the metabolism of phenytoin in the human liver cell.
  1. Platelet Aggregation Inhibitor Pathway, Pharmacodynamics
    Effects of antiplatelet drugs on platelet aggregation pathway.
  1. Proton Pump Inhibitor Pathway, Pharmacokinetics
    Omeprazole metabolism in the liver.
  1. Sorafenib Pharmacokinetics
    Schematic representation of sorafenib metabolism in human liver cell.
  1. Statin Pathway - Generalized, Pharmacokinetics
    Representation of the superset of all genes involved in the transport, metabolism and clearance of statin class drugs.
  1. Tacrolimus/Cyclosporine Pathway, Pharmacokinetics
    Schematic representation of tacrolimus and cyclosporine metabolism
  1. Tamoxifen Pathway, Pharmacokinetics
    Diagram showing candidate genes for tamoxifen metabolism in the liver.
  1. Taxane Pathway, Pharmacokinetics
    Representation of the genes involved in the metabolism and transport of paclitaxel and docetaxel, and the downstream effects of the drugs.
  1. Theophylline Pathway, Pharmacokinetics
    Schematic representation of theophylline metabolism in human liver.
  1. Tramadol Pharmacokinetics
    Schematic representation of tramadol metabolism in human liver cell.
  1. Venlafaxine Pathway, Pharmacokinetics
    Stylized cells depicting the metabolism and mechanism of action of venlafaxine.
  1. Vinka Alkaloid Pathway, Pharmacokinetics
    Representation of the genes involved in the metabolism, transport, and downstream effects of the vinca alkaloid vincristine.
  1. Warfarin Pathway, Pharmacokinetics
    Representation of the candidate genes involved in transport, metabolism and clearance of warfarin.
  1. Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics
    Representation of candidate genes involved in the metabolism of zidovudine and its mechanism of antiviral action.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MIR27A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
NR1I2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
NR1I3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
VDR

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
1,7-dimethylxanthine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
3,4-methylenedioxymethamphetamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
6,7-dihydroxybergamottin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
abacavir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
abiraterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
acamprosate
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
acenocoumarol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
acetaminophen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aflatoxin b1
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alectinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
alfentanil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aliskiren
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
almotriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alosetron
alprazolam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amantadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ambrisentan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amifostine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aminophenazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amiodarone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amitriptyline
amlodipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amodiaquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amoxicillin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amphetamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ampicillin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
anastrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
apomorphine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
aprepitant
aripiprazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aripiprazole lauroxil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
arsenic trioxide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
arteether
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
artemether
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
artemisinin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
artesunate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
asparaginase
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aspirin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
astemizole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
atazanavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
atenolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
atomoxetine
atorvastatin
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
axitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
azacitidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
azathioprine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
azithromycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aztreonam
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
belinostat
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
benztropine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bevacizumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
biperiden
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
boceprevir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bosutinib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
brentuximab vedotin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
brexpiprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bromazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bromocriptine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
budesonide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
buprenorphine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bupropion
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
buspirone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
busulfan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cabazitaxel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cabergoline
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cabozantinib
caffeine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
calcium
carbamazepine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
carboplatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
carisoprodol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
carvedilol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cefaclor
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cefadroxil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cefradine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cefuroxime
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
celecoxib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cephalexin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ceritinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
cerivastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cetuximab
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cevimeline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chloramphenicol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chloroquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
chlorpheniramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chlorpromazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chlorzoxazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cholecalciferol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cholestyramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
cilostazol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cimetidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ciprofloxacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
cisapride
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
cisplatin
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available PW
citalopram
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
clarithromycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clindamycin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clobazam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clofibrate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
clomipramine
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
clopidogrel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clotrimazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clozapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
cocaine
codeine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
conjugated estrogens
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
coumarin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
crizotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cyclobenzaprine
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
cyclophosphamide
cyclosporine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cyproheptadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cytarabine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dabrafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
danazol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
dapsone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
darifenacin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
darunavir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dasatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
daunorubicin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
debrisoquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
decitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
demeclocycline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
desflurane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
desipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
desloratadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dexamethasone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dexfenfluramine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dexlansoprazole
dextromethorphan
diazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diclofenac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dicloxacillin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
didanosine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dienestrol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
digoxin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
diltiazem
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dimenhydrinate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diphenhydramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dirithromycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
disulfiram
docetaxel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
domperidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
donepezil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dopamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
doxepin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
doxorubicin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
doxycycline
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dronedarone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
drospirenone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
drospirenone/ethinyl estradiol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
duloxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
econazole
efavirenz
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eletriptan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eliglustat
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eltrombopag
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
elvitegravir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
emtricitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
enflurane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
entacapone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
epipodophyllotoxin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
epirubicin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
eplerenone
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available PW
erlotinib
erythromycin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
escitalopram
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
esomeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
estradiol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
estrone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eszopiclone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ethambutol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ethanol
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ethinyl estradiol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
etodolac
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
etoposide
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
everolimus
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
exemestane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ezetimibe
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
famotidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
felodipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fenfluramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fenofibrate
fentanyl
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fesoterodine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fexofenadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
finasteride
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flibanserin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flunarizine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
flunitrazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
fluorouracil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
fluoxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluphenazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flurazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flurbiprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
fluticasone propionate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluticasone/salmeterol
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
fluvastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluvoxamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
folic acid
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fosamprenavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
frovatriptan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fulvestrant
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
furafylline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
furosemide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
galantamine
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available PW
gefitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
gemcitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gemfibrozil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gemifloxacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
glibenclamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
glipizide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
grapefruit juice
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
griseofulvin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
haloperidol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
halothane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hesperidin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydralazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydrochlorothiazide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydrocodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
hydrocortisone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydromorphone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydroxyzine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hyperforin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ibandronate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ibuprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ifosfamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ilaprazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
iloperidone
imatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
imipramine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
indacaterol
indinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
indomethacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
irbesartan
irinotecan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
isoflurane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
isoniazid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
isotretinoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
isradipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
itraconazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivabradine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivacaftor
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivacaftor / lumacaftor
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ixabepilone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ketamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ketoconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
labetalol
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lacosamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lamivudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lamotrigine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lansoprazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lapatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lenalidomide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
lercanidipine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
letrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
leucovorin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
levodopa
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
levomethadyl acetate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
levothyroxine
lidocaine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lisinopril
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lisuride
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lomitapide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lopinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
loratadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lorazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
losartan
lovastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lumefantrine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
maraviroc
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
medroxyprogesterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
medroxyprogesterone/conjugated estrogens
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
meloxicam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
memantine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
meperidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mephenytoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mercaptopurine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metformin
methadone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
methotrexate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
methylcholanthrene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
methylphenidate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
methylprednisolone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metoclopramide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metoprolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metronidazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
miconazole
midazolam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mifepristone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
miglustat
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
minocycline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mirtazapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mitiglinide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
modafinil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mometasone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
montelukast
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
morphine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
moxifloxacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
mycophenolate mofetil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
mycophenolic acid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nafcillin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naltrexone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naproxen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naratriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naringenin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naringin
nateglinide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nefazodone
nelfinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
nevirapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
niacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nicardipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nicotine
nifedipine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nilotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
nisoldipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
nitrendipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nortriptyline
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
olanzapine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
olaparib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
omeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
ondansetron
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oseltamivir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxaliplatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
oxazepam
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxcarbazepine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxiconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxycodone
paclitaxel
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
palonosetron
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
panitumumab
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pantoprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
paroxetine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pazopanib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
peginterferon alfa-2b
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
penicillin v
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pentoxifylline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pergolide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
permethrin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
perphenazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pertuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phenobarbital
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
phenprocoumon
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phenytoin
pimozide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pioglitazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
piperaquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
piroxicam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pitavastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ponatinib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
posaconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pramipexole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prasugrel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pravastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prednisone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prilocaine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
primaquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
probenecid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prochlorperazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
progesterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
proguanil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
promethazine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propafenone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propofol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propoxyphene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
propranolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pyrazinamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
quetiapine
quinidine
quinine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rabeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
raltegravir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ranolazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rasagiline
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
regorafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
repaglinide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
reserpine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ribavirin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rifampin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
rilpivirine
risperidone
ritonavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rofecoxib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ropinirole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rosiglitazone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rosuvastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
roxithromycin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ruxolitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
salbutamol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
salmeterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
saquinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Saracatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
selegiline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sertindole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sertraline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sevoflurane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sibutramine
sildenafil
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
simeprevir
simvastatin
sirolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SN-38
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
sorafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sparteine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
st. john's wort
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
stavudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfamethazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfamethoxazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfaphenazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfinpyrazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfisoxazole
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
sunitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tacrine
tacrolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tadalafil
tamoxifen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tamsulosin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tegaserod
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
telaprevir
telithromycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
telmisartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
temazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
teniposide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tenofovir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terazosin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terbinafine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
terfenadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terodiline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
testosterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tetracycline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
theophylline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thioguanine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thioridazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thiotepa
No Dosing Guideline available DL CA VA No VIP available No VIP available
ticagrelor
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ticlopidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tinidazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tiotropium
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
tipifarnib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tipranavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tizanidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tocilizumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolbutamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolcapone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolterodine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
topotecan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
toremifene
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available PW
tramadol
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trametinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tranylcypromine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trastuzumab
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trastuzumab emtansine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
trazodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tretinoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
triamterene
triazolam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trichostatin A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trihexyphenidyl
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trimipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
troleandomycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
valproic acid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
valsartan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vandetanib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vardenafil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
varenicline
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vemurafenib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available PW
venlafaxine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
verapamil
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
viekira pak
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vilazodone
vincristine
No Dosing Guideline available DL CA VA No VIP available No VIP available
voriconazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vortioxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
warfarin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zalcitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
zaleplon
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
zidovudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
ziprasidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zolmitriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
zolpidem
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zonisamide

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acquired Immunodeficiency Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
acute cellular rejection
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Acute coronary syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adenocarcinoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alcoholism
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Alzheimer Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Anemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Anxiety Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmias, Cardiac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arteriosclerosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arthritis, Juvenile Rheumatoid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arthritis, Rheumatoid
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Asthma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Back Pain
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
bioavailability
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Brain Neoplasms
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Breast Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Hepatocellular
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Carcinoma, Non-Small-Cell Lung
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carcinoma, Renal Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Carcinoma, Small Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular Abnormalities
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carotid Artery Diseases
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Chronic Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colonic Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colorectal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
contralateral breast cancer
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Coronary Artery Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coronary Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Crigler-Najjar Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cushing Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cystic Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Dementia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dementia, Vascular
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Depression
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Depressive Disorder, Major
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Diabetes Mellitus, Type 2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Diarrhea
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug Hypersensitivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug interaction with drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug Toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
dry mouth
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dyslipidaemia
Endometrial Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epidermal Necrolysis, Toxic
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Epilepsy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epilepsy, Absence
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epilepsy, Generalized
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Esophageal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exanthema
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastroesophageal Reflux
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Stromal Tumors
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gilbert's syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gingival Hyperplasia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Graft vs Host Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Headache
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Heart Failure
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
heart transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hematologic Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Hepatitis C, Chronic
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Heroin Dependence
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HIV
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HIV Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hot Flashes
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperbilirubinemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperbilirubinemia, Hereditary
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hypercholesterolemia
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hyperlipidemias
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypersensitivity
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypertension, Pulmonary
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammatory Bowel Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
infusion related reaction
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Kidney Failure
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Kidney Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myeloid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myeloid, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Promyelocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukopenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lewy Body Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lipodystrophy
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
liver transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long QT Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lung Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lung transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lupus Erythematosus, Systemic
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lymphedema
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Malaria
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Melanoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metabolic syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolic Syndrome X
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Migraine without Aura
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Muscular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myalgia unspecified
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Mycoses
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myelodysplastic Syndromes
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Myocardial Infarction
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myoclonic Epilepsy, Juvenile
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nephritis, Interstitial
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
nephrotoxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neurodegenerative Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Neurotoxicity Syndromes
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neutropenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Obesity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Opioid-Related Disorders
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Organ Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Osteomalacia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Osteoporosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Osteosarcoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Ovarian Failure, Premature
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Ovarian Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pain
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Parkinson Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Peptic Ulcer
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Peripheral Nervous System Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Peripheral Vascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pregnancy
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
progression-free survival
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Prostatic Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Psychotic Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rhabdomyolysis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Schizophrenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Seizures
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sleep Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stevens-Johnson Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stomach Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Stroke
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Substance-Related Disorders
therapy-related acute myeloid leukemia (t-ML)
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thrombocytopenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thrombosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tobacco Use Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Torsades de Pointes
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Toxic liver disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
transplant rejection
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
treatment modification
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tremor
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tuberculosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Urinary Incontinence

Publications related to CYP3A4: 540

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population. Omics : a journal of integrative biology. 2016. De Andrés Fernando, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Population pharmacokinetics and pharmacogenetics analysis of Rilpivirine in HIV-1 infected individuals. Antimicrobial agents and chemotherapy. 2016. Aouri Manel, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. Transplantation. 2016. Debette-Gratien Marilyne, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome and sulfotransferase gene variation in north African populations. Pharmacogenomics. 2016. Fernández-Santander Ana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Plasma miR-142 accounting for the missing heritability of CYP3A4/5 functionality is associated with pharmacokinetics of clopidogrel. Pharmacogenomics. 2016. Tang Qian-Jie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert opinion on drug metabolism & toxicology. 2016. Tverdohleb Tatiana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations. Pharmaceutical research. 2016. Gonzalez-Covarrubias Vanessa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. Clinical pharmacokinetics. 2016. Csajka Chantal, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of genome sequencing and clinical genotyping for pharmacogenes. Clinical pharmacology and therapeutics. 2016. Yang Wenjian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients. Clinical transplantation. 2016. Deininger Kimberly M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. European journal of clinical pharmacology. 2016. Atiq Ferdows, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. European journal of clinical pharmacology. 2016. Song Ivy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contrasting exome constancy and regulatory region variation in the gene encoding CYP3A4: an examination of the extent and potential implications. Pharmacogenetics and genomics. 2016. Creemer Olivia J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients. Iranian journal of kidney diseases. 2016. Yousef Al-Motassem, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans. Pharmacogenomics. 2016. Mpeta Bafokeng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. Journal of atherosclerosis and thrombosis. 2016. Yi Xingyang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2016. Hirose Takashi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic or -epigenomic biomarkers in drug treatment - two sides of the same medal?. Clinical pharmacology and therapeutics. 2016. Ingelman-Sundberg Magnus, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2016. González A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016. Hocum Brian Thomas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016. Leusink Maarten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The impact of genetic factors on response to glucocorticoids therapy in IBD. Scandinavian journal of gastroenterology. 2016. Gabryel Marcin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clinical pharmacokinetics. 2015. Vandenberghe Frederik, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional Comparison of Human Colonic Carcinoma Cell Lines and Primary Small Intestinal Epithelial Cells for Investigations of Intestinal Drug Permeability and First-Pass Metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2015. Yamaura Yoshiyuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2015. Tracy Timothy S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. OncoTargets and therapy. 2016. Kus Tulay, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
4beta-Hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?. British journal of clinical pharmacology. 2015. Gjestad Caroline, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy research. 2015. Wang Ping, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. Pharmacogenomics. 2015. Aouam Karim, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In Vitro Kinetic Characterization of Axitinib Metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2015. Zientek Michael A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. European journal of clinical pharmacology. 2015. Moes D J A R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. Pharmacogenetics and genomics. 2015. Wang Danxin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients. British journal of clinical pharmacology. 2015. Monostory Katalin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol. British journal of clinical pharmacology. 2015. Wiesinger Herbert, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015. Hagleitner Melanie M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European heart journal. 2015. Varenhorst Christoph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clinical lung cancer. 2015. Kobayashi Hiroyuki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. International journal of clinical pharmacology and therapeutics. 2015. Zhang Jing-Jing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. Journal of cardiovascular pharmacology. 2015. Luzum Jasmine A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients. Pharmacogenomics. 2015. Li Jia-Li, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
4beta-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. British journal of clinical pharmacology. 2015. de Graan Anne-Joy M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing hematocrit. British journal of clinical pharmacology. 2015. de Jonge Hylke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Multigene predictors of tacrolimus exposure in kidney transplant recipients. Pharmacogenomics. 2015. Pulk Rebecca A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype. Basic & clinical pharmacology & toxicology. 2015. Markert Christoph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP3A4∗18B and CYP3A5∗3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2015. Tao Xing-Ru, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: Efavirenz pathway, pharmacokinetics. Pharmacogenetics and genomics. 2015. McDonagh Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2015. He H-R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics. 2015. Marsh Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. Cancer chemotherapy and pharmacology. 2015. Hamberg P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Molecular cancer therapeutics. 2015. Kendra Kari L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2015. Pallet N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of glinides. Pharmacogenomics. 2015. Chen Miao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity. British journal of clinical pharmacology. 2014. Carls Alexandra, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients. Frontiers in genetics. 2015. Swart Marelize, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation. International journal of clinical and experimental medicine. 2015. Zhu Lin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China. International journal of clinical and experimental pathology. 2015. He Yongjun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: ibuprofen pathways. Pharmacogenetics and genomics. 2014. Mazaleuskaya Liudmila L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hsa-miR-27a is involved in the regulation of CYP3A4 expression in human livers from Chinese Han population. Pharmacogenomics. 2015. Shi Ye, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). Pharmacogenomics. 2015. Sosa-Macias Martha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment. Pharmacogenomics. 2015. Ferraresso Mariano, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics. 2015. Helton Sarah G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis. PloS one. 2015. Shi Wei-Long, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. Xenobiotica; the fate of foreign compounds in biological systems. 2015. House Larry, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. Apellániz-Ruiz Maria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
PPARA gene and phenprocoumon: a new predictor of response variability. Pharmacogenetics and genomics. 2014. Botton Mariana R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SNPs and taxane toxicity in breast cancer patients. Pharmacogenomics. 2014. Bosó Virginia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ivacaftor for patients with cystic fibrosis. Expert review of respiratory medicine. 2014. Wainwright Claire E. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. Pharmacogenetics and genomics. 2014. Kuypers Dirk R J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. The pharmacogenomics journal. 2014. de Jonge H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. British journal of clinical pharmacology. 2014. ter Heine Rob, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Urinary hydrocodone and metabolite distributions in pain patients. Journal of analytical toxicology. 2014. Barakat Neveen H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients. Molecular biology reports. 2014. Sharaki Ola, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients. Pharmacogenetics and genomics. 2014. Abubakar Murtala B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia. The pharmacogenomics journal. 2014. Gézsi A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus. Therapeutic drug monitoring. 2014. Bruckmueller Henrike, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. European journal of clinical pharmacology. 2014. Dutreix Catherine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. Journal of clinical pharmacology. 2014. Robertson Sarah M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Pharmacogenetics and genomics. 2014. Kitzmiller Joseph P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction. Pharmacogenomics. 2014. Leusink Maarten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics. 2014. Gentile Giovanna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. British journal of clinical pharmacology. 2014. Noetzli Muriel, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clinical pharmacology and therapeutics. 2014. Diekstra M H M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clinical pharmacology and therapeutics. 2014. Tsamandouras N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug metabolism and disposition: the biological fate of chemicals. 2014. Filppula Anne M, et al. PubMed
No Dosing Guideline available